Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo, +224

The Lancet

Chemotherapy Versus PlaceboBreast OncologyOncologyClinical TrialsBreast Cancer +5

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples

Takayuki Iwamoto, Naoki Niikura, Rin Ogiya, +11

Scientific Reports

Breast OncologyBrain MetastasesImmunologyPathologyGene Expression Profiling +16

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines

Tsutomu Iwasa, Isamu Okamoto, Minoru Suzuki, +7

Clinical Cancer Research

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

Yusaku Akashi, Isamu Okamoto, Tsutomu Iwasa, +8

British Journal of Cancer

Antitumor ActivityImmunologyImmunotherapyTumor BiologyHumanised Monoclonal Antibody +14

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer

Rin Ogiya, Naoki Niikura, Nobue Kumaki, +12

Oncotarget

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer

Masayuki Takeda, Kazuko Sakai, Masato Terashima, +16

Annals of Oncology

OncologyEngineeringMedicineNext-generation SequencingClinical Application +8

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase

Takafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, +9

Molecular Cancer Therapeutics

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Toshio Shimizu, Takashi Seto, Fumihiko Hirai, +9

Investigational New Drugs

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk

Takeshi Yoshida, Isamu Okamoto, Takafumi Okabe, +5

International Journal of Cancer

Signal TransductionSignaling PathwayTumor MicroenvironmentMedicineReceptor Tyrosine Kinase +13

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs

Tsutomu Iwasa, Isamu Okamoto, Ken Takezawa, +10

British Journal of Cancer